AU8096094A - Use of nicotine substitutes for the treatment of nicotine withdrawal - Google Patents

Use of nicotine substitutes for the treatment of nicotine withdrawal

Info

Publication number
AU8096094A
AU8096094A AU80960/94A AU8096094A AU8096094A AU 8096094 A AU8096094 A AU 8096094A AU 80960/94 A AU80960/94 A AU 80960/94A AU 8096094 A AU8096094 A AU 8096094A AU 8096094 A AU8096094 A AU 8096094A
Authority
AU
Australia
Prior art keywords
nicotine
treatment
substitutes
withdrawal
nicotine withdrawal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU80960/94A
Other languages
English (en)
Inventor
Rajinder P. S Matharu
Indu A Muni
B. Ram Murty
Mahendra K Pandya
F. Howard Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DynaGen Inc
Original Assignee
DynaGen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/145,203 external-priority patent/US5414005A/en
Application filed by DynaGen Inc filed Critical DynaGen Inc
Publication of AU8096094A publication Critical patent/AU8096094A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Addiction (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Degasification And Air Bubble Elimination (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Detergent Compositions (AREA)
AU80960/94A 1993-10-28 1994-10-28 Use of nicotine substitutes for the treatment of nicotine withdrawal Abandoned AU8096094A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14430993A 1993-10-28 1993-10-28
US145203 1993-10-28
US08/145,203 US5414005A (en) 1993-10-28 1993-10-28 Methods and articles of manufacture for the treatment of nicotine withdrawal and as an aid in smoking cessation
US144309 1993-10-28
PCT/US1994/012441 WO1995011678A1 (en) 1993-10-28 1994-10-28 Use of nicotine substitutes for the treatment of nicotine withdrawal

Publications (1)

Publication Number Publication Date
AU8096094A true AU8096094A (en) 1995-05-22

Family

ID=26841884

Family Applications (2)

Application Number Title Priority Date Filing Date
AU80960/94A Abandoned AU8096094A (en) 1993-10-28 1994-10-28 Use of nicotine substitutes for the treatment of nicotine withdrawal
AU10456/95A Abandoned AU1045695A (en) 1993-10-28 1994-10-28 Use of lobeline for the treatment of nicotine withdrawal

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU10456/95A Abandoned AU1045695A (en) 1993-10-28 1994-10-28 Use of lobeline for the treatment of nicotine withdrawal

Country Status (6)

Country Link
EP (1) EP0725640A1 (enExample)
JP (1) JPH09507053A (enExample)
AU (2) AU8096094A (enExample)
CA (1) CA2174747A1 (enExample)
TW (1) TW261531B (enExample)
WO (2) WO1995011679A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE326468T1 (de) 1996-10-30 2006-06-15 Pfizer Pyridon-kondensierte azabicyclische- oder cytisin-derivate, ihre herstellung und verwendung in der suchttherapie
ES2141024B1 (es) * 1997-10-03 2000-10-16 Manzanares Jesus Mari Gonzalez Preparado de accion antinicotinica.
GB2376884A (en) * 2001-06-26 2002-12-31 Peter Hajek Helping smokers stop
US7455654B2 (en) * 2003-10-28 2008-11-25 Alza Corporation Method and apparatus for reducing the incidence of tobacco use
CN103284319A (zh) * 2013-06-20 2013-09-11 昌宁德康生物科技有限公司 一种金雀花碱替代尼古丁口腔雾化液及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1017032A (en) * 1963-12-12 1966-01-12 Aerosmoke Ltd Aerosol compositions
GB1056214A (en) * 1964-05-21 1967-01-25 Leo Baum Compositions containing lobeline sulphate
CH658594A5 (de) * 1982-02-22 1986-11-28 Bruss Ni Sanitarno Gigieniches Arzneipraeparat mit antinikotinwirkung und verfahren fuer seine herstellung.
US4665069A (en) * 1985-04-02 1987-05-12 Barnett Rosenberg Analgesic composition and method of relieving pain
GB2230439A (en) * 1989-04-20 1990-10-24 Alec Stanley Walter Shaw Nicotine lozenges

Also Published As

Publication number Publication date
EP0725640A1 (en) 1996-08-14
WO1995011679A1 (en) 1995-05-04
WO1995011678A1 (en) 1995-05-04
TW261531B (enExample) 1995-11-01
AU1045695A (en) 1995-05-22
CA2174747A1 (en) 1995-05-04
JPH09507053A (ja) 1997-07-15

Similar Documents

Publication Publication Date Title
AU7545594A (en) Implantable device for the treatment of aedemas
GB2265297B (en) Sterilisation process in the manufacture of snuff
AU7567394A (en) Treatment chamber catheter
AU7931194A (en) Apparatus for treatment of the oral cavity
AU7205894A (en) Purified natural and synthetic compounds for the treatment of osteoarthritis
AU4525396A (en) Process for the preparation of perfluorocarbons
IL114128A0 (en) Composition for the treatment of nicotine craving and/or smoking withdrawal symptoms
AU3375693A (en) Method of the treatment of dry nose syndrome
AU1115095A (en) Treatment of cellulose
AU3268893A (en) New tobacco substitutes
EP0510503A3 (en) Process for the treatment of surfaces
AU1279788A (en) Compounds and treatment
IL114129A0 (en) Composition for the treatment of nicotine craving and/or smoking withdrawal symptoms
AU5581594A (en) Cigarette and process for preparing the cigarette
AU4090289A (en) Method for the treatment of wool
AU7310896A (en) Use of nitroflavonoids for the treatment of anxiety
AU1116895A (en) Use of theophylline for the manufacture of a medicament for the treatment of asthma
AU2806692A (en) Medicament for the treatment of anxiety
IL114130A0 (en) Composition for the treatment of nicotine craving and/or smoking withdrawal symptoms
EP0674707A4 (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF LEUCOMA.
AU6927894A (en) 4-amidinophenylsulphonamides for the treatment of thrombo-embolitic conditions
AU8096094A (en) Use of nicotine substitutes for the treatment of nicotine withdrawal
AU3028492A (en) Process for the manufacture of 2-alkoxymethylacrolein
AU4812393A (en) Use of rapamycin in the treatment of aids
IL105285A0 (en) Compositions for the treatment of diabetes